LEVI-04: Pain & Function Relief in Osteoarthritis – A p75NTR Approach

A new treatment approach for osteoarthritis of the knee is showing promise, according to the results of a Phase II clinical trial. The study, involving over 510 participants, indicates that LEVI-04, a novel neurotrophin-3 (NT-3) inhibitor, significantly improved pain and function in patients with knee osteoarthritis without evidence of the rapid joint deterioration sometimes seen with other pain therapies. This offers a potential new avenue for managing a condition that affects millions worldwide and for which current treatment options are often limited.

Understanding Osteoarthritis and the Role of Neurotrophins

Osteoarthritis (OA) is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. It’s a leading cause of disability, particularly among older adults. While current treatments focus on managing symptoms – often with pain relievers and physical therapy – there’s a significant need for therapies that address the underlying biological processes driving the disease. Recent research has implicated neurotrophins, proteins that play a role in the growth, survival, and differentiation of neurons, in the development and progression of OA pain. Specifically, excess neurotrophins are thought to contribute to the sensitization of pain pathways in the joint.

Previous attempts to target nerve growth factor (NGF), another neurotrophin, for pain relief showed initial promise but were hampered by a concerning side effect: accelerated osteoarthritis and potential joint damage. LEVI-04 takes a different approach. Instead of directly inhibiting NGF, it’s designed to supplement the body’s natural p75 neurotrophin receptor (p75NTR) binding protein. This action aims to inhibit NT-3 activity and restore neurotrophin homeostasis, potentially providing pain relief while preserving joint health. The p75NTR-Fc fusion protein essentially acts as a ‘scavenger’ for excess neurotrophins, returning the system to a more balanced state. Levicept’s science page provides a detailed explanation of this mechanism.

Phase II Trial Details and Key Findings

The Phase II randomized, double-blind, placebo-controlled trial, identified as NCT05618782, was conducted across multiple centers in Europe and Hong Kong. Participants with painful (rated 4/10 or higher on the WOMAC scale) and radiographically confirmed knee osteoarthritis (KL≥2) were randomly assigned to receive either placebo or varying doses (0.3, 1, or 2mg/kg) of LEVI-04 administered intravenously every four weeks for 16 weeks.

The primary endpoint of the study was the change in WOMAC pain scores from baseline to week 17. Secondary endpoints included measures of function, patient global assessment (PGA), the proportion of patients achieving 50% and 70% pain reduction, a novel assessment of pain during movement (the Staircase-evoked Pain Procedure, or StEPP), and daily pain scores measured using a numerical rating scale (NRS). According to findings published in Osteoarthritis Imaging, LEVI-04 met all primary and secondary endpoints, demonstrating significant improvements in pain and function across all measured parameters. Importantly, the study found no evidence of increased joint deterioration compared to placebo, addressing a key concern raised by previous NGF-targeting therapies.

Study Limitations and Considerations

It’s crucial to note that this was a Phase II trial, designed primarily to assess safety and preliminary efficacy. While the results are encouraging, they do not definitively prove that LEVI-04 will be effective in all patients with knee osteoarthritis. Further research, including larger Phase III trials, is needed to confirm these findings and to evaluate the long-term safety and efficacy of the treatment. The study population was also limited to individuals with radiographic evidence of knee OA, meaning the results may not be generalizable to those with early-stage disease or different types of osteoarthritis. The trial also focused specifically on knee OA. the effectiveness of LEVI-04 in other affected joints remains unknown.

What In other words for Patients and the Future of OA Treatment

The positive results from this Phase II trial offer a glimmer of hope for individuals living with the chronic pain and disability of knee osteoarthritis. The approach of modulating neurotrophin activity, rather than directly inhibiting NGF, appears to be a promising strategy for providing pain relief without the risk of accelerating joint damage. However, it’s important to emphasize that LEVI-04 is still under development and is not yet available for clinical leverage. Patients should continue to follow the guidance of their healthcare providers regarding current treatment options for osteoarthritis, which may include physical therapy, pain medications, and, in some cases, joint replacement surgery.

The findings also highlight the growing understanding of the complex biological mechanisms underlying osteoarthritis pain. By targeting specific pathways involved in pain signaling, researchers are moving closer to developing more effective and targeted therapies that address the root causes of the disease, rather than simply masking the symptoms. The full study published in Osteoarthritis Imaging details the methodology and results in greater depth.

Next Steps in LEVI-04 Development

The developers of LEVI-04 are now preparing for Phase III clinical trials, which will involve a larger and more diverse patient population. These trials will be critical for confirming the efficacy and safety of the treatment and for determining the optimal dosage and administration schedule. Regulatory submissions to health authorities, such as the FDA in the United States and the EMA in Europe, will follow successful completion of Phase III trials. If approved, LEVI-04 could represent a significant advance in the treatment of osteoarthritis and potentially other chronic pain conditions. Ongoing monitoring and surveillance will be essential to assess the long-term effects of the treatment and to identify any potential safety concerns that may emerge over time.